Targeted fusion biopsies of the prostate find more high risk tumours

In an article published in the journal JAMA the authors compared targeted prostate biopsy compared to standard extended sextant biopsies in 1003 men suspected to have prostate cancer. MRI/USS fusion biopsy detected 30% more high risk prostate cancers than standard biopsy. An additional benefit was that the targeted technique picked up17% fewer low risk cancers. When radical prostatectomy specimens from 170 men were examined, targeted biopsies had a higher PPV for intermediate and high risk cancers than standard biopsies.